UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO of United Therapeutics) exercised 9,500 stock options and sold the resulting 9,500 common shares held by a family trust on August 4, 2026 under a 10b5‑1 plan, generating roughly $4.9 million in proceeds.

On August 4, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equivalent number of common shares, then immediately sold those 9,500 shares in a series of open‐market transactions at prices ranging from approximately $512.49 to $520.49 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The option exercise added 9,500 shares to the trust’s indirect common stock holdings, while the sales disposed of the same 9,500 shares for aggregate proceeds of roughly $4.9 million, leaving the reporting person and related family trusts with substantial remaining indirect ownership, including 324,443 common shares in the particular trust executing the trades and additional indirect holdings and options across other family trusts and a spouse account. These transactions represent a structured option exercise-and-sell program rather than a net increase or decrease in the CEO’s economic exposure to United Therapeutics stock.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000113

Alert Tier

7